

ALTERNATIVE TO PTO/SB/08A/B (Based on PTO 03-08 version)

Complete if Known Substitute for form 1449/PTO 10/814.555 Application Number Filing Date March 30, 2004 INFORMATION DISCLOSURE Matthew D. LINNIK STATEMENT BY APPLICANT First Named Inventor Art Unit 1633 (Use as many sheets as necessary) Examiner Name F. Sajjadi Sheet 1 1 Attorney Docket Number 252312008000

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

TONEIGHT ATENT BOODMERTO					
Examiner	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines,
Initials*		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>3</sup> (if known)			Where Relevant Passages Or Relevant Figures Appear

Examiner	Date
Signature	Considered

EXAMINER: Initial 8 information considered, whether or not clasion is in conformance with MPEP 600. Down this through clastion if not in conformance and not considered, whether or not clasion is in conformance with MPEP 600. Down this through clastion if not in conformance and not considered, included copy of this form with next commerciation to applicant. "Applicants unique clastics destinguished manufact (options). See Kribs Codes or Applicants unique clastics of classification and control of the proper of the classification and classification and control of the proper of the classification and one of the proper of the pro

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
F.G.S.	1.	Anonymous (2000). "The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)," located at <a href="http://www.asnrt.net/forum/upload/05%20KF2.2%20SLEDAI.pdf">http://www.asnrt.net/forum/upload/05%20KF2.2%20SLEDAI.pdf</a> , last visited on April 18, 2008, <i>Kidney Forum</i> 2:2:3-24.			
	2.	BARR, S.G. et al. (December 1999). "Patterns of Disease Activity in Systemic Lupus Erythematosus," Arthritis & Rheumatism 42(12):2682-2688.			
	3.	Non-Final Office Action mailed on March 19, 2007, for U.S. Patent Application No. 10/219,238, filed on August 13, 2002, 9 pages.			
	4.	Non-Final Office Action mailed on August 22, 2007, for U.S. Patent Application No. 11/373,699, filed on March 10, 2006, 11 pages.			
	5.	Non-Final Office Action mailed on August 31, 2007 for U.S. Patent Application No. 11/613,987, filed on December 20, 2006, 11 pages.	Γ		
	6.	Non-Final Office Action mailed on October 12, 2007, for U.S. Patent Application No. 10/748,541, filed on December 29, 2003, 9 pages.	Г		
	7.	Final Office Action mailed on April 30, 2008, for U.S. Patent Application No. 11/373,699, 11 pages.			
$\bigvee$	8.	TUMLIN, J.A. et al. (2004). "Reductions in 24-Hour Unine Protein Levels Associated with Treatment of SLE Patients with LIP394 in Two Randomized, Placebo-Controlled Clinical Trials," abstract presented at the American Society of Nephrology Annual Scientific Meeting, St. Louis, MO, Cotber 27-November 1, 2004, located at <a href="http://www.lipc.com/abstracts/abstract_2004_18.html">http://www.lipc.com/abstracts/abstract_2004_18.html</a> , last visited on February 14, 2008, 2 pages.			

Examiner Signature	/Fereydoun Sajjadi/	Date Considered	09/10/2008
PEYAMING	Initial if reference considered whether as not eitating in in	4	at the set of the set

considered. Include copy of this form with next communication to applicant is to place a check mark here if English language Translation is attached.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.